Select Page

Press Release

Celsense, Inc. to Give Presentation at the International Society for Cell Therapy 2017 Annual Meeting

March 1, 2017 – Pittsburgh, PA

Dr. Brooke M. Helfer, the Director of R&D at Celsense, Inc., will give a presentation and participate a panel discussion on Saturday May 6, 2017 at the International Society for Cell Therapy (ISCT) Annual Meeting. The meeting is being held at the Excel Center in London, UK, on May 4, 5, and 6.

Dr. Helfer’s presentation is part of a special session organized by the HESI Emerging Issue Sub-committee – Cell Therapy Tracking Circulation and Safety (CT-TRACS) entitled “Identifying and Optimizing Technologies to Evaluate Cell Therapy Safety, Mode of Action, and Efficacy.” Other speakers at this session will include Dr. Bill Shingleton (GE Healthcare), Dr. Nubuhiro Umeda (Astellas Pharmaceuticals), Dr. Jeff Bulte (Johns Hopkins University), and Dr. Yoji Sato (NIHS).

Founded in 1992, this year marks the 25th anniversary for ISCT. This year’s meeting program is organized around cell and gene therapies, and tissue engineering applications. The meeting is expected to draw over 1,500 attendees. ISCT’s mission is to drive the translation of Cell Therapies for patients worldwide. Please visit for full information about the meeting, including registration.

About Celsense, Inc.
Celsense, Inc. develops and offers novel pre-clinical and clinical-grade products that enable the non-invasive imaging of cells in vivo using MRI. The company’s lead product Cell Sense is a patented fluorocarbon tracer agent used to safely and efficiently label cells ex vivo without the use of transfection agents. Cell Sense is the subject of a Drug Master File at US FDA and Health Canada, and is the only clinical grade MRI cell tracking reagent available in North America. Using software developed by Celsense, investigators can quantify the number of labeled cells in a user-specified region of interest. Celsense’s mission is to be the standard for cellular imaging in human health..

Contact Information:

Charlie O’Hanlon, President and CEO
Celsense, Inc.
(412) 263-2870

Continue Exploring



Real-Time Results,<br />Faster and More Accurate

Celsense offers products that enable real-time MRI detection of inflammation and cellular therapeutics. The mission of the company is to be the standard for cellular imaging in human health.

Send Us A Message

1 + 6 =

© 2020 Celsense, Inc. All rights reserved.